Lolamicin

Lolamicin is an experimental antibiotic. It targets Gram-negative bacteria without significantly affecting typical gut microbes. Lolamicin was discovered by a team led by Paul Hergenrother at the University of Illinois Urbana-Champaign and was first reported in 2024.

In a mouse model of bacterial infection, lolamicin was found to be especially effective against Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae.

Lolamicin works by interfering with the lipoprotein transport system of Gram-negative bacteria.